Label-Free Electrogenerated Chemiluminescence Aptasensing Method for Highly Sensitive Determination of Dopamine via Target-Induced DNA Conformational Change.

A label-free electrogenerated chemiluminescence (ECL) aptasensing method for highly sensitive determination of dopamine (DA) was developed based on target-induced DNA conformational change. After anti-DA specific aptamer, as molecular recognition element, was hybridized with a capture ss-DNA (complementary with the aptamer), the formed double-strand DNA (ds-DNA) was self-assembled onto the surface of a gold electrode, and then Ru(phen) 3 2+ , as ECL reagent, was intercalated into ds-DNA to form an ECL biosensing platform. In the presence of DA, DA bound with its aptamer and target-induced DNA conformational change occurred, resulting in the dissociation of ds-DNA, the release of intercalated Ru(phen) 3 2+ from the electrode surface, and the decrease of ECL intensity. For comparison, an ECL aptamer-based biosensing method using an ECL reagent-labeled aptamer was also developed for DA assay based on target-induced DNA conformational change. Because of the increase in the amount of ECL reagent into ds-DNA over that of the single-site ECL reagent-labeled aptamer, an obvious increase of ECL intensity was found at the ds-DNA modified electrode over the aptamer modified electrode. DA can be sensitively detected with a lower detection limit of 0.05 nM in the range from 0.1 to 100 nM. With the recognition of the aptamer for DA, DA can be selectively and sensitively detected in artificial cerebrospinal fluid and serum samples without interference from common small molecules. This work demonstrates that the combination of the direct transduction of specific recognition of DA and its aptamer into an ECL signal with Ru(phen) 3 2+ intercalated ds-DNA amplification provides a promising strategy for the development of a simple, sensitive, and selective method for DA assay, which is of great importance in neurochemical assays and clinical diagnosis.